Pharmacology and Pharmacogenetics of Chemotherapeutic Agents

被引:20
作者
Dawood, Shaheenah [1 ]
Leyland-Jones, Brian [2 ,3 ]
机构
[1] Dubai Hosp, Dept Oncol, Dubai, U Arab Emirates
[2] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
Personalized medicine; Pharmacogenetics; Pharmacokinetics; Chemotherapy toxicity; ADVERSE DRUG-REACTIONS; DIHYDROPYRIMIDINE DEHYDROGENASE; POLYMORPHISM; TAMOXIFEN; CANCER; METABOLISM; GENE; BIOTRANSFORMATION; 5-FLUOROURACIL; VARIANT;
D O I
10.1080/07357900802574660
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The last decade the field of oncology has seen the introduction of several efficacious chemotherapeutic agents. However the benefits achieved have been modest at best. The choice of chemotherapeutic agent is often empirical and geared to fit the average patient with the result that 40% of patients may be receiving the wrong drug. With greater understanding of the mechanisms behind the heterogeneity observed across patient populations, both in terms of efficacy and toxicity of a variety of therapeutic agents, research has now focused on individualizing treatment strategies by incorporating a combination of physiological variables, genetic characteristics and environmental factors together with the traditional tumor characteristics that currently drives clinical decision making. This review focuses on defining some of the principle components of personalized medicine. In addition we will review the pharmacological and pharmacogenetic predictors of toxic effects of chemotherapeutic agents drawing on examples of commonly used agents in oncology.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 37 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Analysis of the direct cost of adverse drug reactions in hospitalised patients
    Bordet, R
    Gautier, S
    Le Louet, H
    Dupuis, B
    Caron, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (12) : 935 - 941
  • [3] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [4] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
    Desta, Z
    Ward, BA
    Soukhova, NV
    Flockhart, DA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) : 1062 - 1075
  • [5] EGORIN MJ, 1985, CANCER RES, V45, P6502
  • [6] POPULATION STUDY OF DIHYDROPYRIMIDINE DEHYDROGENASE IN CANCER-PATIENTS
    ETIENNE, MC
    LAGRANGE, JL
    DASSONVILLE, O
    FLEMING, R
    THYSS, A
    RENEE, N
    SCHNEIDER, M
    DEMARD, F
    MILANO, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) : 2248 - 2253
  • [7] SURVEY OF THE HUMAN ACETYLATOR POLYMORPHISM IN SPONTANEOUS DISORDERS
    EVANS, DAP
    [J]. JOURNAL OF MEDICAL GENETICS, 1984, 21 (04) : 243 - 253
  • [8] GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN
    EVANS, DAP
    MANLEY, KA
    MCKUSICK, VA
    [J]. BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) : 485 - 491
  • [9] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491
  • [10] FLOCHART DA, 2005, MINI S, P4